

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 5/A

KERYX BIOPHARMACEUTICALS INC

Form 5/A

February 20, 2002

OMB APPROVAL

OMB Number:
Expires:
Estimated average burden
hours per response 1.0

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 5/A

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940

Check this box if no longer subject of Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).

Form 3 Holdings Reported

Form 4 Transactions Reported

=====

1. Name and Address of Reporting Person*

Rosenwald Lindsay A.

(Last) (First) (Middle)

787 Seventh Avenue

(Street)

New York NY 10019

(City) (State) (Zip)

=====

2. Issuer Name and Ticker or Trading Symbol

Keryx Biopharmaceuticals, Inc. (KERX)
=====

3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)

=====

4. Statement for Month/Year

2001
=====

5. If Amendment, Date of Original (Month/Year)

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 5/A

February 2002

6. Relationship of Reporting Person to Issuer
(Check all applicable)

- | | |
|---|--|
| <input checked="" type="checkbox"/> Director | <input checked="" type="checkbox"/> 10% Owner |
| <input type="checkbox"/> Officer (give title below) | <input type="checkbox"/> Other (specify below) |

7. Individual or Joint/Group Filing (Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

* If the Form is filed by more than one Reporting Person, see Instruction 4(b) (v).

Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (mm/dd/yy)	3. Transaction Code (Instr. 8)	4. Security Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Amount	(A) or (D)	Price
Common Stock	04/20/01	G(1)	D	500,000	D	--

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 5/A

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly

(1) Reflects a gift to Ronsenwald Foundation, Inc.

FORM 5 (continued)

Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				(A) (D)		Amount or Number of Shares
Option	\$9.25	5/23/01	A	5,000	(1) 5/23/11	Common Stock 5,000

Explanation of Responses:

(1) 2,500 vest on November 23, 2001; 2,500 vest on May 23, 2002; provided that at the time of vesting, the recipient is a member of the Board of

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 5/A

Directors.

/s/ Lindsay A. Rosenwald

February 14, 2002

**Signature of Reporting Person

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.